Hormone replacement therapy

A method of treating or inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.

A method of inhibiting or retarding bone demineralization or treating or inhibiting osteoporosis in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.

A method of treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.

A method of treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease;

• providing neuroprotection or cognition enhancement in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.

A pharmaceutical composition for use in treating menopausal or postmenopausal disorders, which comprises a dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a dosage of between 0.03 mg and about 0.0625 mg of trimegestone, and a pharmaceutical carrier.

A pharmaceutical dosage unit which comprises which comprises conjugated estrogens, a dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a dosage of between 0.03 mg and about 0.0625 mg of trimegestone, and a pharmaceutical carrier.

A method of minimizing or reducing levels of breast pain in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.

A method of minimizing spotting or breakthrough bleeding;

• or achieving amenorrhea in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.

A method of increasing bone mineral density in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.2 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.03 mg and about 0.0625 mg of trimegestone.